Teva Pharmaceutical Industries Limited (TEVA) News
Track canonical SquawkNews coverage tagged to TEVA, Teva Pharmaceutical Industries Limited. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 66 indexed stories across 25 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Teva Pharmaceuticals Gets FDA Approval for Bone Drug as Biosimilar
By Katherine HamiltonTeva Pharmaceuticals received approval from the Food and Drug Administration for its drug Degevma as a biosimilar to the bone-cancer treatment Xgeva.Degevma is indicated to prevent bone complications
REGULATION | Sep 28, 2026, 08:56 PM UTC
L
Teva Pharmaceutical Industries Ltd. (TEVA) Wins FDA Nod For Xgeva Biosimilar
Teva received FDA approval for DEGEVMA (denosumab-adet), a biosimilar to Xgeva, and plans to launch it alongside PONLIMSI in the U.S. in the coming months.Material DetailsContext by AI AnalystThis is a mid-cycle confirma
REGULATION | Sep 28, 2026, 08:02 PM UTC
H
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™
GEOPOLITICS | Sep 28, 2026, 08:02 PM UTC
L
Teva Pharmaceuticals: Compiled Document With Public Info Previously Provided by Teva to Assist Investors Ahead of 3Q Results, Expected to Be Released Nov 3 >TEVA
Teva Pharmaceuticals: Compiled Document With Public Info Previously Provided by Teva to Assist Investors Ahead of 3Q Results, Expected to Be Released Nov 3 >TEVA
NEWS | Sep 23, 2026, 08:53 PM UTC
L
Teva Pharmaceuticals: Releases 3Q 2026 Aide Memoire
Teva Pharmaceuticals: Releases 3Q 2026 Aide Memoire
NEWS | Sep 23, 2026, 08:53 PM UTC
L
TEVA - Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
TEVA - Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
EARNINGS | Sep 23, 2026, 08:45 PM UTC
L
TEVA - Teva Releases Q3 2026 Aide Memoire
TEVA - Teva Releases Q3 2026 Aide Memoire
NEWS | Sep 23, 2026, 08:45 PM UTC
L
Teva Pharmaceuticals Price Target Announced at $50.00/Share by Oppenheimer
Ratings actions from Benzinga: GMT) Teva Pharmaceuticals Initiated at Outperform by OppenheimerRatings actions from Benzinga
NEWS | Sep 23, 2026, 12:19 PM UTC
M
Teva issues about $4.9B in notes; shifts ADS to NYSE
Teva Pharmaceutical Industries is refinancing debt with roughly $4.9B/€1.5B in notes and converting its ADS into ordinary shares for NYSE trading.
MNA | Sep 21, 2026, 11:29 AM UTC
L
TEVA - New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
TEVA - New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
NEWS | Sep 18, 2026, 08:32 PM UTC
L
Teva posts Phase 3 post hoc data on olanzapine LAI
Teva reported post hoc analyses from the Phase 3 SOLARIS trial on once-monthly subcutaneous olanzapine LAI TEV-749, including stabilization and low relapse rates, and data supporting direct switching from oral or short-a
EQUITY | Sep 18, 2026, 08:31 PM UTC
L
TEVA - Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
TEVA - Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
NEWS | Sep 18, 2026, 08:31 PM UTC
L
TEVA - Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
TEVA - Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
NEWS | Sep 18, 2026, 08:30 PM UTC
M
Delhi High Court quashes Teva tax case, orders 783 cr refund
The Delhi High Court quashed more than a decade-old tax proceedings against Teva Pharmaceutical Industries and its US affiliate tied to a Ranbaxy Laboratories deal, and reprimanded tax authorities for withholding a 783 c
EQUITY | Sep 17, 2026, 04:17 AM UTC
M
Teva issues €1 bln of 4.250% senior notes due 2033
Teva Pharmaceutical Finance Netherlands II has issued EUR 1.0 billion of 4.250% senior notes due 2033.
RATES | Sep 16, 2026, 08:39 PM UTC
H
Teva issues multi-tranche notes worth $3.2B and €1.5B
Teva completed a multi-currency senior unsecured notes offering totaling $3.2 billion and €1.5 billion to refinance debt and enhance financial flexibility.
EQUITY | Sep 16, 2026, 08:33 PM UTC
L
TEVA - Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
TEVA - Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
NEWS | Sep 16, 2026, 12:00 PM UTC
H
Delhi HC orders tax dept to refund Rs.783 cr to Teva Israel over Ranbaxy payment
New Delhi, Sept. 15 -- The Delhi High Court on Tuesday quashed tax proceedings against Israeli drugmaker Teva Pharmaceutical Industries Ltd. and its US affiliate arising from a deal with Ranbaxy Laboratories, and ordered
GEOPOLITICS | Sep 15, 2026, 02:22 PM UTC
H
Teva's Shares Now Trade Directly on the NYSE — Here's What Else Changed
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ) had a busy week that included a major debt refinancing, a milestone shift in how its shares trade on the NYSE and analyst activity. Teva stock is trading near recent high
LIVE | Sep 15, 2026, 12:49 PM UTC
L
Teva begins NYSE trading of ordinary shares as ADS program terminates
Teva began trading its ordinary shares on the New York Stock Exchange and terminated its ADS program.Key Highlights:Original SEC Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ] - 8-K - Sep. 14, 2026This is an AI-powe
REGULATION | Sep 14, 2026, 08:15 PM UTC
L
Teva prices $4.9bn equivalent senior notes, issues five tranches maturing 2032—2037
Teva priced approximately $4.9 billion (equivalent) of senior notes across five tranches and expects settlement on or about September 16, 2026.Key Highlights:Original SEC Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA
REGULATION | Sep 11, 2026, 08:13 PM UTC
L
Teva prices $4.9B senior notes to refinance higher-cost debt
MACRO | Sep 10, 2026, 10:51 AM UTC
L
Teva prices $4.9 billion-equivalent senior notes
EQUITY | Sep 10, 2026, 10:04 AM UTC
L
Leerink Partners sets Teva price target at $45
Leerink Partners announced a $45.00 per-share price target for Teva.
EQUITY | Sep 09, 2026, 03:50 PM UTC
H
S&P upgrades Teva to BBB- as MFN talks and notes plan progress
Teva Pharmaceutical Industries Ltd (TEVA) gained investment-grade status after S&P upgraded it to BBB-. Teva also joined nine drugmakers in MFN talks tied to at least $19.6B in U.S. manufacturing investment and plans EUR
EQUITY | Sep 07, 2026, 11:23 AM UTC
L
Teva launches senior notes offering
Teva announced the launch of an offering of senior notes.
EQUITY | Sep 07, 2026, 07:53 AM UTC
L
UBS maintains Buy rating on Teva Pharmaceuticals
UBS maintained a Buy rating on Teva Pharmaceuticals, according to Benzinga ratings actions.
EQUITY | Sep 04, 2026, 06:43 PM UTC
L
S&P Global Ratings upgrades Teva to BBB
S&P Global Ratings upgraded Teva’s credit rating to BBB-. The move marks the third credit rating upgrade in recent months.
EQUITY | Sep 04, 2026, 03:30 PM UTC
M
TEVA’s TEV-408 shows favorable phase II-A celiac results
TEV-408, an anti-IL-15 antibody, demonstrated statistically and clinically meaningful gut-architecture protection and inflammation reduction in a phase II-A celiac disease study, with favorable safety and symptom trends.
EQUITY | Sep 02, 2026, 02:20 PM UTC
M
TEVA’s TEV-408 posts robust phase IIa celiac results
TEVA’s anti-IL-15 antibody TEV-408 showed statistically and clinically significant gut-architecture protection and reduced inflammation in a phase IIa celiac disease study, with a favorable safety profile and symptom-imp
EQUITY | Sep 02, 2026, 01:27 PM UTC
M
Teva’s celiac drug meets main goal in mid-stage trial
Teva said its experimental immune-disorder drug helped prevent gluten-related intestinal damage in adults with celiac disease, meeting the main goal of its mid-stage trial. U.S.-listed shares were up over 4% in premarket
EQUITY | Sep 02, 2026, 12:02 PM UTC
M
TEVA’s TEV-408 posts positive Phase 2a topline in celiac disease
TEV-408 (anti-IL-15) reported positive Phase 2a topline results in celiac disease, including prevention of gluten-induced intestinal damage and improved symptoms after a single subcutaneous dose.
EQUITY | Sep 02, 2026, 11:16 AM UTC
M
Teva’s TEV ‘408 meets Phase 2a celiac primary endpoint
A Phase 2a study of TEV ‘408 in celiac disease met its primary endpoint, showing significant prevention of gluten-induced intestinal damage and favorable effects on inflammation and symptoms. Drug was well-tolerated.
EQUITY | Sep 02, 2026, 11:16 AM UTC
M
Teva reports positive Phase 2a topline celiac disease results
Teva said its Phase 2a study in celiac disease for its anti-IL-15 antibody delivered positive topline results, further validating its pipeline-in-a-product potential.
EQUITY | Sep 02, 2026, 11:03 AM UTC
L
TEVA - Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
TEVA - Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
EQUITY | Sep 01, 2026, 08:30 PM UTC
L
White House deal targets lower US drug prices via $19.6B infusion
White House deal with mid-size drugmakers includes a $19.6B infusion into US plants aimed at lowering drug prices.
GEOPOLITICS | Aug 31, 2026, 10:44 PM UTC
L
Trump announces drug pricing deals with Teva and 8 others
TradingView News reports that Trump announced drug pricing deals with Teva and eight other companies.
EQUITY | Aug 31, 2026, 09:53 PM UTC
L
Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies
Trump Administration Reaches Most-Favored-Nation Drug Pricing Deals With 9 Companies
GEOPOLITICS | Aug 31, 2026, 08:45 PM UTC
L
TEVA and Trump Administration plan agreement on affordable medicines
TEVA says it and the Trump Administration intend to reach an agreement on affordable medicines and U.S. supply-chain security for patients.
EQUITY | Aug 31, 2026, 08:06 PM UTC
H
BioXcel files Chapter 11, names Teva stalking horse bidder
BioXcel Therapeutics began voluntary Chapter 11 proceedings and entered an asset sale agreement with Teva Pharmaceuticals International GmbH, with Teva set as stalking horse bidder in a court-supervised auction.
RATES | Aug 28, 2026, 03:06 PM UTC
L
Teva Sinks on Bid to Buy BioXcel
Teva Sinks on Bid to Buy BioXcel
EQUITY | Aug 28, 2026, 01:56 PM UTC
M
Teva proposes acquisition of novel neuroscience product
Teva announced a proposed acquisition of a novel neuroscience product.
MNA | Aug 28, 2026, 12:04 PM UTC
H
BioXcel files for bankruptcy, agrees asset sale to Teva
BioXcel filed for bankruptcy and agreed to sell assets to Teva.
EQUITY | Aug 28, 2026, 10:30 AM UTC
M
Teva announces proposed acquisition of novel neuroscience product
Teva says it has proposed an acquisition of a novel neuroscience product as part of its pivot to a growth strategy.
MNA | Aug 28, 2026, 10:17 AM UTC
M
Aurinia says Teva generic voclosporin may launch after 2036
Aurinia Pharmaceuticals says Teva may launch a generic version of voclosporin in the U.S. no earlier than December 7, 2036, while patent litigation continues in New Jersey.
REGULATION | Aug 19, 2026, 08:06 PM UTC
L
Aurinia settles U.S. patent litigation with Teva over voclosporin
Aurinia Pharmaceuticals says it has settled patent litigation with Teva over generic voclosporin in the U.S.
REGULATION | Aug 19, 2026, 08:05 PM UTC
M
TEVA FDA accepts NDA for ecopipam, targets late Q1 2027
TEVA says the FDA has accepted its NDA for ecopipam and set a targeted action date in late Q1 2027.
REGULATION | Aug 19, 2026, 12:30 PM UTC
M
TEVA NDA for ecopipam gets FDA priority review
TEVA says the U.S. FDA accepted its new drug application for ecopipam and granted priority review for the investigational Tourette syndrome therapy in pediatric patients.
REGULATION | Aug 19, 2026, 12:30 PM UTC
L
Teva's Innovative Drug Portfolio Fuels Growth as Company Raises Outlook, Transitions to Direct NYSE Listing
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA ) stock is trading higher on Wednesday after the company reported second-quarter earnings and a direct U.S. listing. • Teva Pharmaceutical Indus shares are powering higher.
EARNINGS | Jul 29, 2026, 05:57 PM UTC
H
Teva CEO: Emalex Acquisition to be Accretive Very Fast
Teva expects Emalex acquisition to be accretive soon
MNA | Jul 29, 2026, 01:45 PM UTC
L
TEVA +7.1% after Co forecasts 2026 profit above estimates
TEVA +7.1% after Co forecasts 2026 profit above estimates
EQUITY | Jul 29, 2026, 01:42 PM UTC
M
Teva CEO: Hopes To Launch Ecopipam In 2027
Teva plans ecopipam launch
EQUITY | Jul 29, 2026, 12:11 PM UTC
L
Teva Pharmaceutical Indus Lowers FY2026 Adj EPS Guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 Est; Raises FY2026 Sales Guidance from $16
Teva Pharmaceutical Indus (NYSE: TEVA ) lowers FY2026 Adj EPS guidance from $2.57-$2.77 to $1.91-$2.11 vs $2.04 analyst estimate. Raises FY2026 sales outlook from $16.400 billion-$16.800 billion to $16.500 billion-$16.85
EARNINGS | Jul 29, 2026, 11:20 AM UTC
L
Teva posts Q2 sales $4.1B, EPS $0.02
Teva reports Q2 sales and EPS
EARNINGS | Jul 29, 2026, 11:10 AM UTC
L
TEVA +4.2% premarket after Co forecasts 2026 profit above estimates
TEVA +4.2% premarket after Co forecasts 2026 profit above estimates
EQUITY | Jul 29, 2026, 11:08 AM UTC
M
Teva Replaces ADS Program
Teva replaces ADS program with direct listing
EQUITY | Jul 29, 2026, 11:08 AM UTC
L
TEVA Teva RESULTS: Q2, Q2 Net Income $-575M, Q2 REV $4.142B, Q2 ADJ EPS $0.02, Teva Earnings Notes:, Outlook FY REV $16,500-16.850B, Outlook
TEVA Teva RESULTS: Q2, Q2 Net Income $-575M, Q2 REV $4.142B, Q2 ADJ EPS $0.02, Teva Earnings Notes:, Outlook FY REV $16,500-16.850B, Outlook FY ADJ EPS $1.91-2.11
EARNINGS | Jul 29, 2026, 11:03 AM UTC
H
TEVA raises guidance
TEVA raises guidance
EQUITY | Jul 29, 2026, 11:01 AM UTC
L
TEVA - Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot t
TEVA - Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
EARNINGS | Jul 29, 2026, 11:00 AM UTC
H
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.
Implied EPS movers for tomorrow AM: PG +/-3.4%, APH +/-11.5%, VRT +/-11.2%, ADP +/-5.0%, FLEX +/-20.8%, SOFI +/-8.5%, BSX +/-7.1%, HUM +/-7.8%, GD +/-3.7%, TEVA +/-6.5%, JCI +/-7.8%, CTSH +/-11.7%, ODFL +/-8.3%, ETR +/-4
EARNINGS | Jul 28, 2026, 06:05 PM UTC